Reinvestigation of tryptophan-dehydrobutyrine diketopiperazine structure

Arkivoc

Volumn 2005, Issue 9, 2005, Pages 30-38

  Avendaño, Carmen ^a   Cabezas, Nieves ^a   De La Cuesta, Elena ^a   Francisco Gonzalez J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Aldol type condensation; N acetylation; Piperazinediones; TDD

Indexed keywords

METHYL GROUP; NATURAL PRODUCT; NITROGEN; PIPERAZINE DERIVATIVE; TRYPTOPHAN; TRYPTOPHAN DEHYDROBUTYRINE DIKETOPIPERAZINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG STRUCTURE; DRUG SYNTHESIS; ISOMER; RACEMIZATION; STRUCTURE ANALYSIS;

EID: 15444374990     PISSN: 14246376     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Tew, K.D.; Bomber, A.M.; Hoffman, S.J. Cancer Res. 1988, 48, 3622
2. See, for example, (a) Potentiation of the non-selective inhibitor ethacrynic acid in: O'Dwyer, P., LaCreta, F.; Nash, S.; Tinsley, P.; Schidler, R.; Clapper, M.; Tew, K.; Panting, L.; Litwin, S.; Comis, R.; Ozols, R. Cancer Res. 1991, 51, 6059. (b) Design of isozyme-specific inhibitors in: Lyttle, M. H.; Hocker, M. D.; Hui, H. C.; Caldwell, C. G.; Aaron, D. T.; Engqvist-Goldstein, A.; Flatgaard, J. E.; Bauer, K. E. J. Med. Chem. 1994, 37, 189.
3. See, for example, (a) Potentiation of the non-selective inhibitor ethacrynic acid in: O'Dwyer, P., LaCreta, F.; Nash, S.; Tinsley, P.; Schidler, R.; Clapper, M.; Tew, K.; Panting, L.; Litwin, S.; Comis, R.; Ozols, R. Cancer Res. 1991, 51, 6059. (b) Design of isozyme-specific inhibitors in: Lyttle, M. H.; Hocker, M. D.; Hui, H. C.; Caldwell, C. G.; Aaron, D. T.; Engqvist-Goldstein, A.; Flatgaard, J. E.; Bauer, K. E. J. Med. Chem. 1994, 37, 189.
4. (a) Wang, A. L.; Tew, K. D. Cancer Treat. Rep. 1985, 69, 677.
5. (b) Batist, G.; Tulpule, A.; Sinha, B.K.; Katki, A.G.; Myers, C.E., Cowan, K.H. J. Biol. Chem. 1986, 25, 15544.
6. (c) Buller, A.L.; Clapper, M.L.; Tew, K.D. Mol. Pharmacol. 1987, 31, 575.
7. (d) Czerwinski M.; Gibbs J. P.; Slattery J. T: Drug Metab. Dispos. 1996, 24, 1015.
8. (a) Samuelsson, B. Science, 1983, 220, 568.
9. (b) Ouwerkerk-Mahadevan, S.; Boom, J. H.; Dreef-Tromp, M. C.; Ploemen, J. H. T. M.; Meyer, D. J.; Mulder, G. J. Biochem. J. 1995, 308, 283.
10. Sipos, E. P.; Witham, T. F.; Ratan, R.; Burger, P. C.; Baraban, J.; Li, K. W.; Piantadosi, S.; Brem, H. Neurosurgery, 2001, 48, 392.
11. (a) Zhang, K.; Mack, T.; Kim, P.W. Int. J. Oncol. 1998, 12, 871.
12. (b) Lyon R.P.; Hill, J. J.; Atkins, W. M. Biochemistry, 2003, 42, 10418.
13. Bach, M. K.; Brashler, J. R.; White, G. J.; Galli, S. J. Biochem. Pharmacol. 1987, 36, 1461.
14. (a) Komagata, D.; Sawa, T.; Muroaka, Y.; Imada, C.; Okami, Y.; Takeuchi, T. J. Antibiot. 1992, 45, 1117.
15. (b) Komagata, D.; Takahashi, Y.; Muraoka, Y.; Sawa, T.; Takeuchi, T. J. Antibiot. 1992, 45, 1122.
16. (c) Komagata, D.; Sawa, R.; Kinoshita, N.; Imada, C.; Sawa, T.; Naganawa, H.; Hamada, M.; Okami, Y.; Takeuchi, T. J. Antibiot. 1992, 45, 1681.
17. (a) Kakinuma, K.; Rinehart, K. L. J. Antibiot. 1974, 27, 733.
18. (b) Santamaría, A.; Cabezas, N.; Avendaño, C. Tetrahedron 1999, 55, 1173.
19. (a) Avendaño, C.; Menéndez, J. C. Curr. Med. Chem. 2002, 9, 159.
20. (b) Avendaño, C.; Menéndez, J. C. Med. Chem. Rev.-Online 2004, 1, 419.
21. See, for example: Johnson, A.-J.; Janosik, T.; Bergman, J. ARKIVOC, 2002, viii, 55-61 and last papers on this topic from our laboratory: (a) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron Lett. 2003, 44, 4395. (b) González, J. F.; de la Cuesta, E.; Avendaño, C. Synthetic Commun. 2004, 34, 1589. (c) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron. 2004, 60, 6319.
22. See, for example: Johnson, A.-J.; Janosik, T.; Bergman, J. ARKIVOC, 2002, viii, 55-61 and last papers on this topic from our laboratory: (a) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron Lett. 2003, 44, 4395. (b) González, J. F.; de la Cuesta, E.; Avendaño, C. Synthetic Commun. 2004, 34, 1589. (c) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron. 2004, 60, 6319.
23. See, for example: Johnson, A.-J.; Janosik, T.; Bergman, J. ARKIVOC, 2002, viii, 55-61 and last papers on this topic from our laboratory: (a) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron Lett. 2003, 44, 4395. (b) González, J. F.; de la Cuesta, E.; Avendaño, C. Synthetic Commun. 2004, 34, 1589. (c) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron. 2004, 60, 6319.
24. See, for example: Johnson, A.-J.; Janosik, T.; Bergman, J. ARKIVOC, 2002, viii, 55-61 and last papers on this topic from our laboratory: (a) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron Lett. 2003, 44, 4395. (b) González, J. F.; de la Cuesta, E.; Avendaño, C. Synthetic Commun. 2004, 34, 1589. (c) González, J. F.; de la Cuesta, E.; Avendaño, C. Tetrahedron. 2004, 60, 6319.
25. 9a
26. Radhakrishna, A. S.; Prasad, R. K.; Suri, S. K.; Sivaprakash, K.; Singh, B. B. Synth. Commun. 1991, 21, 379.
27. Hernández, F.; Lumetzberger, A.; Avendaño, C.; Söllhuber, M. Synlett, 2001, 1387.